GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TOT Biopharm International Co Ltd (HKSE:01875) » Definitions » Financial Strength

TOT Biopharm International Co (HKSE:01875) Financial Strength : 5 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is TOT Biopharm International Co Financial Strength?

TOT Biopharm International Co has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

TOT Biopharm International Co's Interest Coverage for the quarter that ended in Jun. 2024 was 5.74. TOT Biopharm International Co's debt to revenue ratio for the quarter that ended in Jun. 2024 was 0.37. As of today, TOT Biopharm International Co's Altman Z-Score is 0.04.


Competitive Comparison of TOT Biopharm International Co's Financial Strength

For the Biotechnology subindustry, TOT Biopharm International Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TOT Biopharm International Co's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TOT Biopharm International Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where TOT Biopharm International Co's Financial Strength falls into.



TOT Biopharm International Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

TOT Biopharm International Co's Interest Expense for the months ended in Jun. 2024 was HK$-4 Mil. Its Operating Income for the months ended in Jun. 2024 was HK$24 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$339 Mil.

TOT Biopharm International Co's Interest Coverage for the quarter that ended in Jun. 2024 is

Interest Coverage=-1*Operating Income (Q: Jun. 2024 )/Interest Expense (Q: Jun. 2024 )
=-1*23.966/-4.178
=5.74

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

TOT Biopharm International Co's Debt to Revenue Ratio for the quarter that ended in Jun. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Jun. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(74.108 + 339.156) / 1120.904
=0.37

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

TOT Biopharm International Co has a Z-score of 0.04, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of 0.04 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TOT Biopharm International Co  (HKSE:01875) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

TOT Biopharm International Co has the Financial Strength Rank of 5.


TOT Biopharm International Co Financial Strength Related Terms

Thank you for viewing the detailed overview of TOT Biopharm International Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


TOT Biopharm International Co Business Description

Traded in Other Exchanges
N/A
Address
120 Changyang Street, Suzhou Industrial Park, Suzhou, CHN, 215024
TOT Biopharm International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families as well as medical professionals. It has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). It generates revenues from Mainland China.
Executives
Center Laboratories, Inc. 2201 Interest of corporation controlled by you
Tricor Trust (hong Kong) Limited 2301 Trustee
Chengwei Evergreen Capital, Lp 2101 Beneficial owner
Center Laboratories Inc. 2101 Beneficial owner
Chengwei Evergreen Management, Llc 2201 Interest of corporation controlled by you
Suzhou Vivo Management Consulting Partnership (limited Partnership)
Vivo (suzhou) Health Industry Investment Fund (limited Partnership)
Vivo Capital Llc
Vivo Capital Viii, Llc
Vivo Capital Fund Viii, L.p.
Prime Success International Limited 2101 Beneficial owner
Advantech Capital Ii L.p.
Advantech Capital Ii Master Investment Limited
Advantech Capital Investment V Limited
Advantech Capital Partners Ii Limited

TOT Biopharm International Co Headlines

No Headlines